Get access

Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Palmar Hyperhidrosis: A Double-Blind, Randomized, Placebo-Controlled Study

Authors


  • N. J. LOWE, MD HAS RECEIVED RESEARCH GRANTS AND CONSULTANT PAYMENTS, AND OWNS STOCK IN ALLERGAN, INC.

Address correspondence and reprint requests to: Nicholas J. Lowe, MD, Clinical Research Specialists, Inc., 2001 Santa Monica Blvd., Suite 490W, Santa Monica, CA 90404, or e-mail: nlowecrs@aol.com.

Abstract

background. Recent studies demonstrate that botulinum toxin type A (BTX-A) decreases palmar hyperhidrosis.

objective. To evaluate the efficacy and safety of BTX-A for palmar hyperhidrosis.

methods. Patients (n = 19) received injections of placebo (normal saline) in one hand and BTX-A in the other. Assessments included gravimetric measurement of sweat production and physician's and patient's rating of severity. Safety evaluations included measuring grip strength. Preliminary 28-day results are reported.

results. The mean percentage decrease in gravimetric measurement at day 28 was significantly greater with BTX-A versus placebo. One hundred percent of 17 patients rated the treatment as successful, while only 12% (2/17) rated placebo injection successful. Grip and hand strength were unchanged with either treatment. Only 21% (4/19) reported mild adverse events.

conclusion. BTX-A injections produce significant improvements in palmar hyperhidrosis without a concomitant decrease in grip or dexterity, or the occurrence of serious adverse events.

Ancillary